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Vaccine developmentBackground: Malaria in pregnancy is associated with significant morbidity in pregnant women and their
offspring. Plasmodium falciparum infected erythrocytes (IE) express VAR2CSA that mediates binding to
chondroitin sulphate A (CSA) in the placenta. Two VAR2CSA-based vaccines for placental malaria are
in clinical development. The purpose of this study was to evaluate the robustness and comparability of
binding inhibition assays used in the clinical development of placental malaria vaccines.
Methods: The ability of sera from animals immunised with different VAR2CSA constructs to inhibit IE
binding to CSA was investigated in three in vitro assays using 96-well plates, petri dishes, capillary flow
and an ex vivo placental perfusion assay.
Results: The inter-assay variation was not uniform between assays and ranged from above ten-fold in the
flow assay to two-fold in the perfusion assay. The intra-assay variation was highest in the petri dish
assay. A positive correlation between IE binding avidity and the level of binding after antibody inhibition
in the petri dish assay indicate that high avidity IE binding is more difficult to inhibit. The highest binding
inhibition sensitivity was found in the 96-well and petri dish assays compared to the flow and perfusion
assays where binding inhibition required higher antibody titers.
Conclusions: The inhibitory capacity of antibodies is not easily translated between assays and the high
sensitivity of the 96-well and petri dish assays stresses the need for comparing serial dilutions of serum.
Furthermore, IE binding avidity must be in the same range when comparing data from different days.
There was an overall concordance in the capacity of antibody-mediated inhibition, when comparing
the in vitro assays with the perfusion assay, which more closely represents in vivo conditions.
Importantly the ID1-ID2a protein in a liposomal formulation, currently in a phase I trial, effectively
induced antibodies that inhibited IE adhesion in placental tissue.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Infection with Plasmodium falciparum in pregnancy is associated
with maternal anemia, low birth weight and stillbirths [1,2]. The
infected erythrocytes (IE) adhere to chondroitin sulphate A (CSA)in the placenta [3]. The binding is mediated by the P. falciparum
erythrocyte membrane protein 1 VAR2CSA [4]. After exposure to
P. falciparum during pregnancy, women develop VAR2CSA specific
antibodies protecting them during subsequent pregnancies [5,6].
Substantial evidence suggests that antibodies inhibiting the
VAR2CSA-CSA binding convey protection against placental malaria
[7,8]. Although opsonising antibodies might contribute to immu-
nity [9], activated monocytes and macrophages might cause
pathology [10]. Therefore, the induction of anti-adhesive VAR2CSA
IgG is the focus for vaccine design. Two VAR2CSA based vaccines
are currently in phase I clinical trials [11,12]. The large full-
length VAR2CSA protein may not be feasible as a vaccine, and iden-
tification of a construct that elicits protective antibodies has been a
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structs to elicit anti-adhesive antibodies in animals has been eval-
uated using different binding inhibition assays. Commonly used
binding inhibition assays in vaccine development are: (i) a high-
throughput 96-well assay [13], (ii) a petri dish assay [14] and
(iii) a flow assay [15]. The 96-well and petri dish assays are static
assays where IEs bind to chondroitin sulphate proteoglycan (CSPG)
coated onto plastic surfaces, where after non-adherent cells are
washed off. The flow assay use channels or chambers coated with
CSA [15], CSA-expressing cells such as BeWo [16] or primary tro-
phoblast [17], or placental cryosections [18]. A weakness of
in vitro models is the difficulty of translating IE binding inhibition
to the in vivo situation and to which degree they represent corre-
lates of immunity.
We recently described adhesion of P. falciparum IEs in a more
biologically relevant placental perfusion model, where IE circulate
through the intervillous space of a non-fixed intact human placen-
tal cotyledon [19].
It has not been established to which degree results from binding
inhibition studies can be translated between assays. Laboratories
involved in vaccine development have used different assays com-
plicating interpretation and comparison of vaccine candidate per-
formance. Identification of potential surrogate measures of
protection could reduce duration of clinical trials to measure the
efficacy of a placental malaria vaccine. Therefore, an understanding
of performance of the different assays will be important for the fur-
ther clinical development of VAR2CSA based placental malaria vac-
cines. The objective of this study was to evaluate the robustness
and read-outs of binding inhibition assays used for clinical devel-
opment of placental malaria vaccines.2. Materials and methods
2.1. Parasite cultures
Parasite isolates were cultured in vitro as previously described
[20,21]. FCR3 parasite cultures were selected for binding to BeWo
cells (purchased from American Type Culture Collection (http://
www.lgcpromochem-atcc.com) [22,23], producing an isolate
exclusively expressing VAR2CSA [20]. Cultures were regularly
analysed for mycoplasma infection and genetic identity verified
by PCR [24,25].2.2. Protein production
The recombinant full-length VAR2CSA antigen and VAR2CSA
constructs were produced as described (Table 1) [26–28]. All pro-Table 1
Protein production and immunisations.
Sera VAR2CSA construct Expression system Species A
1 FV2d Baculoc Rabbit Fr
2 ID1-DBL4 Baculoc Rabbit Fr
3 ID1-ID2a S2b Rabbit Fr
4 ID1-ID2a S2b Rabbit A
5 ID1-ID2a S2b Mouse ID
6 FV2d Baculoe Rat Fr
7 ID1-ID2a S2b Rat A
8 NTS-ID2a E. coli Rat A
9 DBL3-4 Baculoc Rat Fr
10 DBL2-3 Baculoc Rat Fr
a Primary dose in Freund’s complete adjuvant (Sigma-Aldrich) followed by booster in
b Expression using the pExpreS2-1 plasmid (Expres2ion) in Droshophila Schneider 2 c
c Expression using the baculovirus vector pAcGP67-A (BD Bioscience) in High-Five ins
d FV2: Full-length VAR2CSA.teins were quality controlled by reduced and non-reduced SDS
page, ELISA and western blot [27,29].
2.3. Immunizations
Rat (Wistar (inbred), Taconic, Denmark) antisera were produced
as previously described [30]. Rabbit (New Zealand White (out-
bred), HB Lidköping Kaninfarm, Sweden) FV2 antisera were pro-
duced by subcutaneous injection and collected 10–14 days after
the final boosting injection. The proteins for rat and rabbit immu-
nisations were adjuvanted with Freund’s adjuvant (Sigma-Aldrich)
or Alhydrogel (Statens Serum Institut, Denmark). Mice ID1-ID2a
antisera were produced in adult mice (C57bl/6 (inbred), Taconic,
Denmark) by intra-muscular injection. The protein was adjuvanted
with a liposomal formulation (Infectious Disease Research Insiti-
tute, Seattle, USA) [31]. Groups of 8 mice were immunized and sera
were collected 7 days after the final boosting injection and pooled.
An overview of constructs and immunizations is shown in
Table 1.
2.4. Binding inhibition assays
2.4.1. 96-well assay
A high-throughput binding assay was performed as described
previously [13]. Briefly, 2  105 tritium-labelled late-stage IE and
immune-sera or control pre-immunization serum from each spe-
cies at 1:10, 1:100, 1:1000 and 1:2000 in were added in triplicates
to wells coated with 2 lg/ml Decorin (D8428; Sigma-Aldrich).
Background binding was evaluated in BSA coated wells. After incu-
bation for 90 min at 37 C, unbound IE were washed off by resus-
pension. The number of adhering IE was determined by liquid
scintillation counting. Three individual experiments were
performed.
A binding ratio was obtained by dividing the median number
bound IE in each sample by the median number bound IE in wells
with IE incubated with pre-immunization sera from the same spe-
cies and at the same concentration.
The inter-assay variation of FCR3-CSA binding was determined
using the mean binding on each day to calculate a coefficient of
variation (CV-standard deviation of the day means/mean of the
day means).
The proportion of IE binding in a well was estimated after deter-
mining the counts per minute/IE in wells with a known number of
IE.
2.4.2. Petri dish assay
The assay was performed as described by Saveria et al. [14] with
some modifications. 22 spots in a Petri dish (Falcon 351029) weredjuvant 96 well Petri dish Flow Perfusion
eund’sa X X X X
eund’sa X X X X
eund’sa X X X X
lhydrogel X X X X
RI LS-127 X X X X
eund’sa X X Not done X
lhydrogel X X Not done X
lhydrogel X X Not done X
eund’sa X X Not done X
eund’sa X Not done Not done X
jections in Freund’s incomplete adjuvant.
ells (Expres2ion).
ect cells (BD Biosciences).
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humidity chamber overnight. Each spot was blocked with 3% BSA
at room temperature for 2 h. 5  106 IE/ml late-stage IE in PBS with
2% FBS were pre-incubated with immune-sera or control pre-
immunization serum from each species at 1:10, 1:100, 1:1000
and 1:2000 dilution for 30 min at room temperature. 20 lL of the
IE/serum suspension or IE control was added to each spot and
allowed to settle for 21 min at room temperature. Background
binding was evaluated on BSA coated spots. Each sample was
tested in duplicate in four individual experiments. Unbound IEs
were washed off with PBS with 2% FBS on a rotation table and
bound IE were fixed with 1.5% Glutaraldehyde. Bound IE were visu-
alized with a Nikon Eclipse TE2000-E and 3 images of each spot
were taken using NIS-Elements F at 10 magnification. IE were
counted in ImageJ and converted to IE/mm2.
A binding ratio was obtained by dividing the median number
bound IE in each sample by the median number bound IE on con-
trol spots with IE incubated with pre-immunization sera from the
same species and at the same concentration.
The inter-assay variation of FCR3-CSA binding was determined
using the mean binding on each day to calculate a CV.
The proportion of IE binding to a spot was estimated using the
formula (IE/mm2⁄spot area)/(added IE/spot).2.4.3. Flow assay
The flow assay was performed mainly as previously described
[32]. Channels (0.04  0.01  2.8 cm (w  h  l)) on biochips
(Vena8Flouro+; Cellix).were coated with 2 lg/ml Decorin in PBS
at 4 C overnight and blocked with 2% BSA in PBS for one hour at
room temperature. FCR3 VAR2CSA cultures were adjusted to 4–
5% late stage trophozoites and 1% hct (corresponding to 1.1  108 -
erythrocytes/ml). IE in RPMI were incubated with serum from
immunized rodents in concentrations 1:10, 1:100 and 1:1000 for
30 min at room temperature. Pre-immunization serum at 1:10
from each species served as control. The samples were centrifuged
at 800g for 12 s and the pellet was resuspended in RPMI with 2%
serum.
Binding of IE was quantified by allowing IE to flow through
channels at 0.5 dyne/cm2 [33] for five minutes and IE adhering in
the channel were counted in five fields at 40 magnification or
in 10 fields at 100 magnification. For each test sera, three inde-
pendent experiments were performed in triplicates.
A binding ratio was determined as the IE binding in the pres-
ence of test sera/IE binding in the presence of control sera.
The inter-assay variation of FCR3-CSA binding was determined
using the mean IE binding in the channels on each day to calculate
a CV.
The proportion of IE binding in the channel was estimated using
the formula (IE/mm2 ⁄ channel surface area (mm2)/(((Time (min) ⁄
flow rate (ll/min)) + channel volume (ll)) ⁄ IE/ll)). Time was
defined as duration of the experiment (5 min) and an average of
2.5 min counting.2.4.4. Placental perfusion assay
Ex vivo perfusion of a placental cotyledon was performed
mainly as previously described [19]. Briefly, the maternal and fetal
circulation of a cotyledon was re-established in a placenta donated
immediately after delivery. Flushing both circulations with med-
ium washed out maternal and fetal blood. The experiments were
performed in 4–5 one-hour phases with IE or IE pre-incubated with
immune-serum in the maternal circulation (1% haematocrit) sepa-
rated by an open-loop wash phase to remove unbound IE and
serum.
The proportion of IE in the maternal circulation was determined
by flow cytometry as previously described [19,34].The binding ratio was expressed as the median percentage
bound IE in the presence of sera relative to the control phase with-
out sera.
Inter-assay variation was calculated using the per cent bound IE
at t = 60 in the control phase of each perfusion and expressed as a
CV.
2.5. Statistical analysis
The inter-assay variation in parasite binding inhibition was
analysed by Spearman rank correlation.
Graphs and statistical analysis were performed in R [35].
2.6. Ethical considerations
The perfusion study was approved by the ethical review board
in Capital Region of Denmark (reference nr H-1-2012-103).
Informed written consent was obtained from participating women.
The animal study was approved by the Danish Animal Experiments
Inspectorate (approval number: 2013-15-2934-00902/BES).
Anaesthesia of mice and rats was initiated by inhalation of 5%
Isoflurane and maintained by 2–3% Isoflurane before full bleed.
Rabbits were anesthetized before full bleed with Ketamine
(35 mg/kg) and Xylazine (5 mg/kg) and euthanized with pentobar-
bital (150 mg/kg). The methods were carried out in accordance
with the approved guidelines for human subjects and experimental
animals.3. Results and discussion
The inhibitory capacity of sera was tested in four binding assays
that are summarised in Table 2. Three in vitro assays test IE binding
to decorin coated on plastic surfaces, while the ex vivo perfusion
assay test binding to placental tissue. The 96-well assay is a stan-
dardized high throughput assay where several plates can be run
simultaneously. Quantification of bound IE relies on the incorpora-
tion of tritium labelled hypoxanthine into the parasite nucleic
acids, followed by liquid scintillation counting [13]. This requires
equipment and facilities for radioactive material, which may limit
the transferability of the assay. Alternatively, colorimetric methods
may be used [36]. The petri dish assay requires a minimum of
equipment and is easily transferred between laboratories [14].
Dilution series of two sera can be accommodated in one dish,
and several dishes can be run simultaneously. Quantification relies
on imaging in a microscope, with either manual or automatic
counting with appropriate software. The flow assay requires a
pump system and associated chips with channels. One sample
can be tested in each channel, and dilution series of 2–3 sera can
be tested in one day. The perfusion system requires a perfusion
chamber, pumps, access to placental tissue and relatively large
amounts of reagents. One condition can be tested in each one-
hour phase and 4–7 phases conducted in one day.
3.1. Potential bias towards assessment of inhibition of sub-populations
of IE
The variation in overall binding of VAR2CSA expressing IE is
shown in Fig. 1 and Table 2. The 96-well assay had the least
inter-assay variation (CV 8%). Due to the high capacity, experi-
ments were performed on only three occasions, which may limit
the variation. The largest inter-assay variation was seen in the flow
assay, where the binding efficiency in control measurements dif-
fered with a factor of 14 between assays performed on different
days. As shown in Fig. 1, the majority of the parasite cultures used
in the flow assay resulted in a low and comparable binding, while
Table 2
Assay overview.
Assay Throughput a Binding
substance
Condition for IE
binding
Washing
method
IE binding quantification % IE binding in control
(median & range)
CV
(%)
96-well High: 6 sera/plate. 10
plates/day
CSPG Static Resuspension Liquid scintillation counting 27 (12–37) 8
Petri dish Medium: 2 sera/plate. 4
plates/day
CSPG Static Flooding,
rotation
Imaging in microscope,
automatic counting
53 (11–95) 33
Flow Low: one sera/channel. 2–3
channels/day
CSPG Flow Continuous
flow
Imaging in microscope, manual
counting
8.9 (3.5–48) 102
Placental
perfusion
Low: one sera/phase. 4–7
phases/day
Placental
tissue
Flow Continuous
flow
Flow cytometry estimation of
IE in circulation
75 (53–92) 15
IE: infected erythrocyte, CV: coefficient of variation (standard deviation of the control binding day means/mean of the control binding day means), CSPG: chondroitin sulphate
proteoglycan
a The number of sera that can be tested/day with the number of concentrations and replicates used in this study.
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Fig. 1. Comparison of the inter- and intra-assay variation. The figure shows variation in binding of FCR3-CSA to decorin or placental tissue within and between days. The
variation between phases/plates/dishes/channels is shown in one boxplot while the day-to-day variation is shown between boxplots. Placental perfusion assay, IE binding (%)
after 60 min perfusion (n = 17 control phases performed in 14 perfusions). 96 well assay, mean IE/well binding on each plate (n = 9 plates performed on 3 days). Petri dish
assay, mean IE/mm2 binding in each petri dish (n = 24 petri dishes performed on 9 days). Flow assay, mean IE/mm2 binding in each channel (n = 15 channels performed on
8 days).
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binding. All cultures used had been cultured according to standard
protocols. This assay is particularly sensitive to temporary obstruc-
tions of flow, which may increase over-all binding. However, in the
case of obstruction, an experiment was terminated and excluded.
Although we did not observe deviations during this study the high
variation demonstrates the fragility of this assay. Also the petri
dish assay had a relatively large inter-assay variation (CV 33%),
as well as a large intra-assay variation (Fig. 1).
The highest proportion of added IE that bound in the assay was
seen in the placental perfusion assay where 75% of the perfused IE
disappeared from the circulation (Table 2). In the petri dish assay
53% of the added IE adhered to spots and in the 96-well assay 27%
of the added IE adhered to the wells. In both the petri dish and
96-well assays, saturation and the wash step intensity may affect
the number of bound IE, leading to an underestimation of the pro-
portion of IE that can bind in the assay. The lowest proportion of
binding was seen in the flow assay, where 8.9% of added IE adhered
in the decorin-coated channel. The strikingly low proportion of
binding in this assay is likely influenced by the flow dynamics inthe channel and the lack of the three-dimensional villous tree,
which architecturemay increase parasite binding. However, the rel-
atively low median binding in this assay may also suggest that the
assay favours binding of a sub-population of high avidity binding IE.
In this study, the same concentration of the CSPG decorin (2 lg/
ml) was used in the in vitro assays. In the flow assay, BeWo cells
[16], human trophoblast cultures [17] and placental cryosections
[18] have been used. While BeWo and human trophoblast cultures
may present a more relevant receptor for IE binding, cell cultures
lack the three-dimensional architecture of the villous tree, which
likely contributes to adhesion.
In the flow assay a shear stress of 0.5 dyne/cm2 was used.
Recent studies suggest that the shear stress on the syncytiotro-
phoblast range between 0.5 ± 0.2 and 2.3 ± 1.1 dyne/cm2, and that
the binding of IE decrease with increasing shear stress [17]. In the
perfusion assay the shear stress on the syncytiotropoblast is not
known due to the complexity of the system. However, the flow rate
in the maternal circulation resembles that of the placenta and the
intervillous flow is mimicked as the perfusate percolates the vil-
lous tree [19].
Table 3
Serum concentration required to obtain 50% binding inhibition.
Serum VAR2CSA construct and adjuvant 96-well assay Petri dish assay Flow assay Perfusion assaya
1 FV2, Freund’s 1:2000 1:2000 1:10 1:100b
5 ID1-ID2a, IDRI LS-127 1:2000 1:1000 1:10 1:100
6 DBL1-6, Freund’s 1:2000 1:100 Not done 1:100
2 ID1-DBL4, Freund’s 1:100 1:100 No inhibition No inhibition
3 ID1-ID2a Freund’s 1:100 1:100 No inhibition No inhibition
7 ID1-ID2a, Alhydrogel 1:100 1:100 Not done No inhibition
8 NTS-ID2a, Alhydrogel 1:100 1:10 Not done No inhibition
4 ID1-ID2a, Alhydrogel 1:10 No inhibition No inhibition No inhibition
9 DBL3-DBL4, Freund’s No inhibition No inhibition Not done No inhibition
10 DBL2-DBL3, Freund’s No inhibition Not done Not done No inhibition
a Concentration in total volume perfusion medium (100 ml). Pre-incubation performed in 10 ml medium.
b A subset of the FV2 inhibition experiments has previously been published by Pehrson et al. [19].
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Fig. 2. Comparison of the assay sensitivity in measuring induction of binding inhibitory antibodies Binding inhibition by (A) rabbit sera, (B) mouse sera, and (C) rat sera. The
y-axis shows the binding ratio of test sera/control sera. The x-axis shows the serum dilution. Individual experiments are shown as circles and the experiment median is
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614 C. Pehrson et al. / Vaccine 35 (2017) 610–6183.2. Differential concentration of immune-serum needed for inhibition
in various assays
The immune-sera used for comparing binding inhibition in the
different assays are shown in Table 3 and the binding inhibitions
are shown in Fig. 2A–C. In general, inhibition was achieved with
low concentrations of immune-sera in the 96-well and petri dishassays, whereas high immune-sera concentrations were required
to obtain inhibition in the flow assay and the placental perfusion
assay. Several sera inhibited well at a low dilution, but failed to
inhibit parasite binding at higher dilutions, demonstrating the
importance to test serum in dilution series in the 96-well and petri
dish assay to be able to compare the inhibitory activity of antibod-
ies induced by homologous vaccines [7,18,26,27,37–41].
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Fig. 2 (continued)
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rabbit and rat) and the minimal CSA binding region, ID1-ID2a, with
a liposomal adjuvant, inhibited parasite binding in the flow and
perfusion assays. There are several possible explanations why it
would be more difficult to inhibit binding in the perfusion model.
It is likely that the IEs have a higher affinity for the oncofetal CSA
[42] in the placenta compared to bovine decorin, therefore higher
antibody levels or affinity may be needed to block that binding.
CSA is abundant in the placenta, and parasites bind both to the syn-
cytiotrophoblast and in the intervillous space in the perfusion
model as in vivo [19,43]. Therefore, IEs are likely to be surrounded
by CSA, enabling a higher avidity binding in placental tissue. In
addition, the blood flow through the intervillous space is slow
[17], which may favour IE adhesion.3.3. Does the overall binding level influence the measured binding
inhibition level?
There was a positive correlation between IE binding in control
measurements and serum binding inhibition at low serum concen-
trations in the petri dish assay (1:2000: rho = 0.58, p < 0.0001,
1:1000: rho = 0.43, p = 0.005, Fig. 3). Therefore, when comparing
the inhibitory capacity of sera analysed in different petri dishes
and on different days, it may be necessary to ensure similar bind-
ing between experiments. A similar, but not statistically significant
effect was seen in the 96-well assay, however, the effect of IE con-
trol binding on measured inhibition was much lower and the assay
therefore appears to be more robust to inter-assay variation. In the
flow assay, there was a trend towards higher binding inhibition
with higher CSA binding, and although only significant at one con-
centration (1:100: rho = 0.50, p = 0.030), it supports the hypothesis
that the low number of bound IE observed in the majority of the
flow experiments represents a subpopulation of strongly adherent
IE. We did not observe a significant correlation between bindingand inhibition in the perfusion assay, however the number of data
points available is not sufficient to draw any conclusions.4. Conclusions
Despite the fact that a highly standardised parasite line under
selection to express VAR2CSA was used, all the CSA binding assays
suffered from considerable inter- and intra-assay variation. This
variation was a factor two-three in the perfusion and 96-well
assays but considerably higher in the petri dish and flow assays.
The binding inhibition results highlight the importance of run-
ning dilution series of immune-serum and assuring comparable
parasite binding between experiments. Choice of assay may
depend on study objective. It is evident that much higher concen-
trations of immune-sera are needed to inhibit parasite binding to
CSA in the placenta as compared to CSA immobilized on plastic.
This is likely due to the fact that in the placenta the overall density
of CSA surrounding the IE will be much higher as compared to a
one dimensional petri dish or a tube. To differentiate constructs
that can elicit inhibitory antibodies in pre-clinical development,
assays with higher sensitivity for detecting binding inhibition, such
as the 96-well and petri dish assays, may be an advantage. These
assays, in particular the 96-well assay, also have a higher capacity.
The perfusion model more closely represents in vivo conditions and
may be more informative regarding the efficacy in humans. How-
ever, the model is resource demanding, which limits the number
of samples that can be tested and the assay is not sensitive to
detect small effects. The overall concordance in determining the
inhibitory capacity of individual sera across the in vitro and
ex vivo assays, demonstrates the possibility of using one of these
assays in a surrogate endpoint after initial smaller vaccine efficacy
trials [44]. Until such data are available, it will not be possible to
determine the level of vaccine-specific antibody-mediated inhibi-
tion that corresponds to protection in vivo, as antibodies acquired
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Fig. 3. Correlation between FCR3-CSA IE binding avidity and antibody mediated binding inhibition. The upper panel shows the petri dish assay, the middle panel shows the
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without VAR2CSA specific antibodies) in each assay relative to the maximum CSA binding observed. The y-axis shows the binding ratio of test sera/control sera (i.e. binding in
the presence of VAR2CSA specific antibodies).
616 C. Pehrson et al. / Vaccine 35 (2017) 610–618in natural infections are also generated against parts of VAR2CSA
that are not included in the vaccine, thus restricting such analysis.
However, we hypothesize that the placental perfusion systemmost
likely reflects the capacity of inhibitory antibodies in vivo. Thus, if a
50% inhibitory capacity (IC50) at 1:100 serum dilution achieved in
the perfusion system corresponds to in vivo protection; a surrogate
endpoint would be an IC50 of 1:2000 dilution in the 96-well assay
and 1:10 dilution in the flow assay based on the results obtained
here. The relationship with inhibition in the petri dish assay
appears less clear, however, petri dish assays are less complex
and relatively easy to transfer between laboratories. In this study
there appears to be a consistent relationship between inhibition
in the 96-well assay and the perfusion assay, which, in
combination with the high throughput of the 96-well assay, may
favour its use in the clinical development of a var2csa-based
vaccine.
The vaccine formulation containing the ID1-ID2a construct with
a potent liposomal adjuvant [31], currently in phase I clinical trials,
was inhibitory in all assays. Sera from mice immunised with this
formulation effectively inhibited parasite adhesion in perfused pla-
cental tissue at a 100-fold dilution. This is an encouraging result,
conferring hope that this formulation will also inhibit parasite
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